1. Signaling Pathways
  2. PI3K/Akt/mTOR
  3. PI3K


PI3K (Phosphoinositide 3-kinase), via phosphorylation of the inositol lipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), forms the second messenger molecule phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3) which recruits and activates pleckstrin homology domain containing proteins, leading to downstream signalling events crucial for proliferation, survival and migration. Class I PI3K enzymes consist of four distinct catalytic isoforms, PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ.

There are three major classes of PI3K enzymes, being class IA widely associated to cancer. Class IA PI3K are heterodimeric lipid kinases composed of a catalytic subunit (p110α, p110β, or p110δ; encoded by PIK3CA, PIK3CB, and PIK3CD genes, respectively) and a regulatory subunit (p85).

The PI3K pathway plays an important role in many biological processes, including cell cycle progression, cell growth, survival, actin rearrangement and migration, and intracellular vesicular transport.

PI3K Isoform Specific Products:

  • PI3Kα

  • PI3Kβ

  • PI3Kγ

  • PI3Kδ

  • PI3KC2α

  • PI3KC2β

  • PI3KC2γ

  • Vps34

  • PI3K

  • PI3KC3

  • p120γ

Cat. No. Product Name Effect Purity
  • HY-19312
    3-Methyladenine Inhibitor 99.84%
    3-Methyladenine是 PI3K 的抑制剂。它通过抑制class III PI3K广泛作为自噬 (autophagy) 的抑制剂使用。
  • HY-10108
    LY294002 Inhibitor 99.95%
    LY294002 是一种广谱 PI3K 抑制剂,抑制 PI3Kα, PI3KδPI3KβIC50 分别为 0.5, 0.57, 0.97 μM。LY294002 也可抑制 CK2 的活性,IC50 为 98 nM。LY294002 是一种竞争性 DNA-PK 抑制剂,可逆结合 DNA-PK 的激酶结构域,IC50 为 1.4 μM。
  • HY-10197
    Wortmannin Inhibitor 99.85%
    Wortmannin (SL-2052) 是一种有效的,选择性的和不可逆的 PI3K 抑制剂,IC50 值为 3 nM。Wortmannin (SL-2052) 阻断自噬形成,并有效抑制 Polo-like kinase 1 (PlK1)Plk3IC50 值分别为 5.8 和 48 nM。
  • HY-15244
    Alpelisib Inhibitor 99.90%
    Alpelisib (BYL-719) 是有效,选择性的 PI3Kα 抑制剂,抑制 p110α/p110γ/p110δ/p110βIC50 分别为 5 nM,250 nM,290 nM,1200 nM 。
  • HY-15346
    Copanlisib Inhibitor 98.91%
    Copanlisib (BAY 80-6946) 是一种 ATP竞争,选择性 I 型 PI3K 抑制剂,作用于 PI3KαPI3KδPI3KβPI3KγIC50 分别为 0.5,0.7,3.7 和 6.4 nM。
  • HY-N1435
    Oroxin B Inhibitor 98.77%
    Oroxin B (OB) 是一种从传统中草药 Oroxylum indicum (L.) Vent 中分离出来的黄酮类化合物。 Oroxin B (OB) 通过上调 PTEN,下调 COX-2,VEGF,PI3K 和 p-AKT,对肝癌细胞具有明显的抑制作用,诱导细胞早期凋亡 (apoptosis)。 Oroxin B (OB) 在恶性淋巴瘤细胞中诱导肿瘤抑制性 ER 应激。
  • HY-N6775
    Sonolisib Inhibitor >99.0%
    Sonolisib (PX-866),一种改良的 Wortmannin 类似物,是一种可口服的,不可逆的,泛亚型的 PI3K 抑制剂 (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ))。PX-866 具有出抗肿瘤活性。
  • HY-N0146
    Quercetin (dihydrate) Inhibitor
    Quercetin (dihydrate) 是一种天然黄酮类化合物,可激活或抑制许多蛋白质的活性。Quercetin (dihydrate) 可激活 SIRT1,也可抑制 PI3K,抑制 PI3K γ,PI3K δ,PI3K β 的 IC50 值分别为2.4 μM, 3.0 μM, 5.4 μM。
  • HY-70063
    Buparlisib Inhibitor 99.90%
    Buparlisib (NVP-BKM120) 是一种 pan-class I PI3K 抑制剂,作用于 p110α/p110β/p110δ/p110γIC50 分别为 52 nM/166 nM/116 nM/262 nM。
  • HY-13026
    Idelalisib Inhibitor 99.98%
    Idelalisib (CAL-101) 是一种口服有效的高选择性 p110δ 抑制剂,IC50 为 2.5 nM,比 p110δ 和其他 PI3K class I 酶的选择性高 40 到 300 倍。
  • HY-18085
    Quercetin Inhibitor >98.0%
    Quercetin是一种天然黄酮类化合物,可激活或抑制许多蛋白质的活性。 槲皮素可激活SIRT1,也可抑制 PI3K,抑制PI3K γ,PI3K δ,PI3K β的 IC50 分别为2.4 μM, 3.0 μM, 5.4 μM。
  • HY-P0175
    740 Y-P Activator
    740 Y-P (PDGFR 740Y-P) 是有效,可渗透细胞的 PI3K 活化物。
  • HY-100716
    IPI549 Inhibitor 99.34%
    IPI549 是一种有效的选择性 PI3Kγ 抑制剂,IC50 为 16 nM。
  • HY-50673
    Dactolisib Inhibitor 99.13%
    Dactolisib (BEZ235) 是一种双重的 pan-class I PI3KmTOR 抑制剂,作用于 p110α/γ/δ/βmTORIC50 分别为 4 nM/5 nM/7 nM/75 nM 和 20.7 nM。Dactolisib (BEZ235) 抑制 mTORC1mTORC2
  • HY-50094
    Pictilisib Inhibitor 99.62%
    Pictilisib (GDC-0941) 是有效的 PI3Kα/δ 抑制剂,IC50为 3 nM;对110β (11倍) 和 p110γ (25倍) 具有适度的选择性。
  • HY-12481
    SAR405 Inhibitor 99.94%
    SAR405 是一流的,选择性的,具有ATP竞争性的 PI3K III (PIK3C3) 亚型 Vps34 抑制剂 (IC50=1.2 nM; Kd =1.5 nM)。SAR405 抑制饥饿或 mTOR 抑制诱导的自噬。具有抗癌活性。
  • HY-12513
    LY3023414 Inhibitor 99.77%
    LY3023414 有效且选择性地抑制 PI3KαPI3KβPI3KδPI3KγDNA-PK,和 mTORIC50 分别为 6.07 nM,77.6 nM,38 nM,23.8 nM,4.24 nM,和 165 nM。在低纳摩尔浓度下,LY3023414 有效抑制 mTORC1/2
  • HY-17044
    Duvelisib Inhibitor 99.91%
    Duvelisib 是一种选择性 p100δ 抑制剂,作用于 p110δ, p110γ, p110β 和 p110α,IC50 分别为 2.5 nM,27.4 nM,85 nM 和 1602 nM。
  • HY-13522
    Fimepinostat Inhibitor 99.95%
    Fimepinostat (CUDC-907) 有效抑制 I 型 PI3K 及 I 和 II 型 HDAC 酶,作用于 PI3Kα/PI3Kβ/PI3Kδ 和 HDAC1/HDAC2/HDAC3/HDAC10 ,IC50 分别为 19/54/39 nM 和 1.7/5.0/1.8/2.8 nM。
  • HY-10115
    PI-103 Inhibitor 99.86%
    PI-103 是一种有效的 PI3K mTOR 抑制剂,抑制 p110αp110βp110δp110γmTORC1mTORC2IC50 分别为 8 nM,88 nM,48 nM,150 nM,20 nM 和 83 nM。PI-103 还抑制 DNA-PK,IC50 为 2 nM。

Phosphatidylinositol 3 kinases (PI3Ks) are a family of lipid kinases that integrate signals from growth factors, cytokines and other environmental cues, translating them into intracellular signals that regulate multiple signaling pathways. These pathways control many physiological functions and cellular processes, which include cell proliferation, growth, survival, motility and metabolism[1]


In the absence of activating signals, p85 interacts with p110 and inhibits p110 kinase activity. Following receptor tyrosine kinase (RTK) or G protein-coupled receptor (GPCR) activation, class I PI3Ks are recruited to the plasma membrane, where p85 inhibition of p110 is relieved and p110 phosphorylates PIP2 to generate PIP3. The activated insulin receptor recruits intracellular adaptor protein IRS1. Phosphorylation of IRS proteins on tyrosine residues by the insulin receptor initiates the recruitment and activation of PI3K. PIP3 acts as a second messenger which promotes the phosphorylation of Akt at Thr308 by PDK-1. RTK activation can also trigger Ras-Raf-MEK-ERK pathway. Activated Akt, ERK and RSK phosphorylate TSC2 at multiple sites to inhibit TSC1-TSC2-TBC1D7, which is the TSC complex that acts as a GTPase-activating protein (GAP) for the small GTPase RHEB. During inhibition of the TSC complex, GTP-loaded RHEB binds the mTOR catalytic domain to activate mTORC1. Glycogen synthase kinase 3β (GSK-3β) activates the TSC complex by phosphorylating TSC2 at Ser1379 and Ser1383. Phosphorylation of these two residues requires priming by AMPK-dependent phosphorylation of Ser1387. Wnt signaling inhibits GSK-3β and the TSC complex, and thus activates mTORC1. mTORC2 is activated by Wnt in a manner dependent on the small GTPase RAC1. Akt activation contributes to diverse cellular activities which include cell survival, growth, proliferation, angiogenesis, metabolism, and migration. Important downstream targets of Akt are GSK-3, FOXOs, BAD, AS160, eNOS, and mTOR. mTORC1 negatively regulates autophagy through multiple inputs, including inhibitory phosphorylation of ULK1, and promotes protein synthesis through activation of the translation initiation promoter S6K and through inhibition of the inhibitory mRNA cap binding 4E-BP1[1][2][3].


PI3Kδ is a heterodimeric enzyme, typically composed of a p85α regulatory subunit and a p110δ catalytic subunit. In T cells, the TCR, the costimulatory receptor ICOS and the IL-2R can activate PI3Kδ. In B cells, PI3Kδ is activated upon crosslinking of the B cell receptor (BCR). The BCR co-opts the co-receptor CD19 or the adaptor B cell associated protein (BCAP), both of which have YXXM motifs to which the p85α SH2 domains can bind. In lumphocytes, BTK and ITK contribute to the activation of PLCγ and promotes the generation of DAG and the influx of Ca2+, which in turn activate PKC and the CARMA1-, BCL 10- and MALT1 containing (CBM) complex. The resulting NF-κB inhibitor kinase (IKK) activation leads to the phosphorylation and the degradation of IκB, and to the nuclear accumulation of the p50-p65 NF-κB heterodimer. MyD88 is an adapter protein that mediates signal transduction for most TLRs and leads to activation of PI3K[4].



[1]. Thorpe LM, et al. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.Nat Rev Cancer. 2015 Jan;15(1):7-24. 
[2]. Vanhaesebroeck B, et al. PI3K signalling: the path to discovery and understanding.Nat Rev Mol Cell Biol. 2012 Feb 23;13(3):195-203. 
[3]. Fruman DA, et al. The PI3K Pathway in Human Disease.Cell. 2017 Aug 10;170(4):605-635.
[4]. Lucas CL, et al. PI3Kδ and primary immunodeficiencies.Nat Rev Immunol. 2016 Nov;16(11):702-714. 

Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.